This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Targovax Oy. Active years: 2021-2023.
Company Filing History:
Years Active: 2021-2023
Title: Antti Vuolanto: Innovator in Cancer Therapy
Introduction
Antti Vuolanto is a notable inventor based in Veikkola, Finland. He has made significant contributions to the field of cancer therapy through his innovative research and patents. With a focus on combining adenoviruses and checkpoint inhibitors, Vuolanto is at the forefront of developing new treatment options for cancer patients.
Latest Patents
Antti Vuolanto holds 2 patents related to his groundbreaking work. His latest patents include a combination therapy that utilizes an oncolytic adenovirus vector alongside checkpoint inhibitors. This invention aims to enhance the effectiveness of cancer treatments by integrating these two therapeutic approaches.
Career Highlights
Vuolanto is currently associated with Targovax Oy, a company dedicated to developing innovative cancer therapies. His work at Targovax has positioned him as a key player in the field of oncology, where he continues to explore new avenues for treatment.
Collaborations
Throughout his career, Antti Vuolanto has collaborated with talented professionals, including Tuuli Ranki and Sari Anneli Pesonen. These collaborations have further enriched his research and contributed to the advancement of cancer therapies.
Conclusion
Antti Vuolanto's contributions to cancer therapy through his innovative patents and collaborations highlight his commitment to improving patient outcomes. His work continues to inspire advancements in the field of oncology.